PR91155

DURHAM, N.C., Aug. 16, 2021 /PRNewswire=KYODO JBN/ --

-- Highly complementary transaction will strengthen company's ability to

support bioanalytical services across all stages, development capabilities and

geographies

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research

laboratory focused on supporting its pharmaceutical and biotech partners in all

stages of large molecule drug development, announced today that it signed a

definitive agreement to purchase 360biolabs(R), the most comprehensive contract

research organization in Australia. The transaction will expand BioAgilytix's

global footprint into a jurisdiction of choice to commence first-in-human

trials (FIH) and early-phase clinical trials and adds further capacity by

joining 360biolabs' internationally recognised Quality systems (ISO/IEC 17025,

ISO 15189, GLP and GCLP) in Melbourne, Victoria with BioAgilytix's existing

laboratories in Durham, North Carolina; Boston, Massachusetts; and Hamburg,

Germany.

Photo - https://mma.prnewswire.com/media/1594905/360biolabs.jpg

Logo - https://mma.prnewswire.com/media/1278852/BioAgilytix_Logo.jpg

Located in Australia's biomedical and clinical research hub, 360biolabs offers

world-class virology and immunology expertise, with BSL 2 and 3 laboratories,

biomarker and immune monitoring capabilities with a state-of-the-art flow

cytometry suite, molecular biology PCR suite and expansive bioanalytical

LC-MS/MS small molecule capabilities.

"This planned acquisition is part of our strategic growth strategy to expand

our capacity, expertise and agility to serve customers across all geographies,

and we look forward to welcoming the 360biolabs team and integrating the

business," said Jim Datin, President and CEO of BioAgilytix. "Joining forces

makes sense for our two organizations, but most importantly for our combined

clients and the patients they serve. BioAgilytix and 360biolabs are already

culturally aligned in our focus on doing science right, on time, the first

time. Together, we will not only create significant scientific synergies but

also generate new innovations and help bring future life-changing therapeutics

to patients more rapidly around the globe."  

"From the launch of 360biolabs in 2015, our strategic vision was to build a

global speciality laboratory, providing support to enable future medicines for

human health," said Angela Luttick, 360biolabs Cofounder and Executive Vice

President, Business Development. Added 360biolabs Cofounder and CEO Alistair

Draffan, "Finding a like-minded partner, driven by a team-focused culture of

excellence with an international reputation, US and European presence, will

drive our strategic expansion and support our clients' clinical development

programs." Melinda Pryor, Cofounder and Executive Vice President, Clinical

stated, "We're excited to join forces with the BioAgilytix team, a company that

shares our strong scientific track record and commitment to quality and

service. Together, we have the capabilities and capacity to meet all

challenges, especially in this time of pandemic, and create enduring

opportunities for a brighter future."

The Burnet Institute, a global medical research and public health organisation,

is a Cofounder and majority shareholder of 360biolabs. Burnet Institute

Director and CEO, Professor Brendan Crabb AC said, "Burnet Institute is proud

of its involvement in the foundation of 360biolabs. It is the right time, with

the growing need for high quality clinical trial support, for a company of the

scale, capability, and reputation of 360biolabs to join with BioAgilytix and

expand their capacity to service their customers and facilitate high quality

translational medical research."

The acquisition is subject to Australian Foreign Investment Review Board

("FIRB") requirements and, subject to receipt of FIRB approval, is expected to

close in the third quarter of 2021. BioAgilytix selected White & Case as legal

counsel to oversee the closing of the acquisition, with Lazard Australia and

Allens representing 360biolabs.

About BioAgilytix

BioAgilytix is a leading bioanalytical testing laboratory specializing in large

molecule bioanalysis. With laboratory locations in North Carolina's Research

Triangle Park, the Cambridge area of Massachusetts, and Hamburg, Germany,

BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay

services supporting the development and release testing of biologics across a

number of industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under

non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product

release testing, stability testing, etc.). BioAgilytix also offers diagnostic

testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix's team of highly experienced scientific and QA professionals

ensures high-quality science, data integrity and regulatory compliance through

all phases of clinical development. BioAgilytix is a trusted partner to many

top global pharmaceutical and biotech companies. For more information, visit

www.bioagilytix.com.

About 360biolabs(R)

360biolabs(R) is the leading and most comprehensive specialty laboratory in the

Australia & New Zealand region. Our expert pharmacokinetic (PK) and

pharmacodynamic (PD) assay services support small molecule, biologic, vaccine

and other innovative therapeutic solutions to human health. A world class and

industry experienced technical team, known for their ability to successfully

deliver technically challenging assays, 360biolabs(R) supports global

Pharmaceutical and biotech companies in a diverse and growing range of

therapeutics areas.

360biolabs(R) delivers global regulatory compliant assays and reports following

ISO/IEC 17025, ISO 15189, OECD GLP, GCLP and ICH GCP with a focus on quality.

For more information, visit www.360biolabs.com.

Media Contact:

Pam O'Connor

BioAgilytix

+1 919-621-1230

pam.oconnor@bioagilytix.com  

SOURCE: BioAgilytix